

Hyewon Ahn

Second Generation Patents in Pharmaceutical Innovation



Nomos

MIPLC

Munich
**Intellectual
Property**
Law Center

Augsburg
München
Washington DC



UNI
Universität
Augsburg
University



THE GEORGE
WASHINGTON
UNIVERSITY
LAW SCHOOL
WASHINGTON DC

MIPLC Studies

Edited by

Prof. Dr. Christoph Ann, LL.M. (Duke Univ.)
Technische Universität München

Prof. Robert Brauneis

The George Washington University Law School

Prof. Dr. Josef Drexler, LL.M. (Berkeley)

Max Planck Institute for Intellectual Property and
Competition Law

Prof. Dr. Thomas M.J. Möllers

University of Augsburg

Prof. Dr. Dres. h.c. Joseph Straus,

Max Planck Institute for Intellectual Property and
Competition Law

Volume 19

Hyewon Ahn

Second Generation Patents in Pharmaceutical Innovation



Nomos

MIPLC Munich Augsburg
Intellectual München
Property Washington DC
Law Center

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <http://dnb.d-nb.de> .

a.t.: Augsburg, Univ., Diss., 2013

ISBN 978-3-8487-0874-1

1. Edition 2014

© Nomos Verlagsgesellschaft, Baden-Baden 2014. Printed in Germany.

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying machine or similar means, and storage in data banks. Under § 54 of the German Copyright Law where copies are made for other than private use a fee is payable to »Verwertungsgesellschaft Wort«, Munich.

Acknowledgements

This dissertation was accepted by the University of Augsburg for the degree of doctor juris in July 2013. The study takes into account statutory and case law available until the end of 2013.

It would not have been possible to write this doctoral thesis without the help and support of people around me, to only some of whom I can give particular mention here.

First and foremost I would like to express my heart-felt gratitude to my supervisor Prof. Dr. Christoph Ann for his continuous support of my PhD study, endless encouragement, patience, and scholarly input. He has always made himself available to clarify my doubts and has been willing to help me to move forward whenever I faced obstacles throughout the whole period of research. Under his constant and invaluable guidance I could successfully overcome many difficulties. For all these reasons and many more, I am eternally grateful.

I would also like to sincerely thank Prof. Dr. Ulrich M. Gassner for his insightful critique and interest in my research and for being the second referee of this thesis.

I will forever be thankful to my second supervisor Prof. Dr. Nari Lee who indeed had recommended that I should pursue the PhD study and always stood beside me, for her guidance, insights and integral view of my research. Her enthusiasm and love for research and teaching has been contagious. I feel privileged to be associated with a person like her during my life.

I am very much indebted to Prof. Dr. Joseph Straus who kindly shared with me his immense knowledge no matter whether he was in his office or even on a cruise, especially for his extensive discussions around my work. And I will remember one of many pieces of advice from him which speeded my research up greatly, i.e. “Well, a PhD thesis is not supposed to save the whole globe.”

I owe Prof. Martin Adelman lots of gratitude for his valuable advice, many thoughtful and detailed comments, as well as constructive criticism throughout the study. He always supported and enlightened me and knew how to make a person moved with one sentence, i.e. “So, how’s your thesis going?”.

Acknowledgements

I am also thankful to Chief Judge Randall R. Rader across the Atlantic who provided me with a great chance to experience and learn how the court system works in the CAFC. I was very much privileged to learn from him and grateful for his encouragement, advice and deep insights into U.S. and comparative patent law.

My sincere gratitude is extended to Prof. Dr. Joseph Drexler for the academic support to carry out the research work at the Institute. I also take this opportunity to acknowledge the Max-Planck Institute for the Intellectual Property and Competition Law that provided a scholarship and thus made my Ph.D. work possible.

I am also thankful to the MIPLC program director, Dr. Gintare Surblyte, who made available her support in many ways.

My time at MPI was made enjoyable in large part thanks to the many friends that now become a part of my life. Ilho Lee deserves special mention here for his constant support and helping me when I faced difficulties or queries throughout my study. I also would like to thank Max Wallot and Eugenio Hoss for their support, helpful discussions and listening to my academic woes. Special thanks must go to Dr. Monica Donghi and Dr. Jörg Habermann for their support for my PhD study as well as kind proofreading with their technical and legal knowledge. I am also grateful to my office colleagues, Nicole van der Laan, Rachel Alemu, Kan He, Magdalena Kolasa, and Seyhan Ugurlu, who went through hard times together, cheered me on, celebrated each accomplishment, and made a stimulating and fun filled environment.

I extend my deep thanks to Kyounghee Paek, Yeonhee Kim, and Jeongeun Lee who helped me to update the development of Korean Jurisprudence and have been there for me as always. Their support, friendship, and belief in me were a treasure and will always be remembered.

Lastly, I would like to thank my parents and my sister. Their love and support all the way from Korea allowed me to finish this journey. I owe them everything and just wish I could show them how much I love and appreciate them.

December 2013

Hyewon Ahn

Inhaltsverzeichnis

List of Abbreviations	15
I. INTRODUCTION	21
A. Overview	21
B. Outline of the dissertation	25
C. Scope of the dissertation	25
II. PHARMACEUTICAL INVENTIONS, INNOVATIONS & PRODUCTS	28
A. Cumulative nature of inventions	28
1. Basic and second generation inventions	29
a) Improvement inventions	30
b) Selection inventions	30
B. Inventions and innovations in pharmaceutical field	32
1. Inventions and patents in pharmaceutical field	32
a) Product invention and the absolute character of its protection	33
b) Hierarchy of pharmaceutical patents	34
2. Innovations in pharmaceutical field	36
a) Invention v. innovation	36
b) NMEs as the core of pharmaceutical innovation	37
C. Second generation inventions and patents in pharmaceuticals	38
1. Product inventions and patents	39
a) Species selection inventions	39
b) Optical isomers	43
c) Crystalline forms	46
d) Metabolites and prodrugs	47
e) Esters and salts	49
f) Dosage forms	49
g) Combinations of active ingredients	50

2. Use inventions	50
a) New Use/New method of treatment	50
b) Dosage regime	52
3. Process inventions	52
a) Process	52
b) Intermediates	53
D. Pharmaceutical products in the market	53
1. New medical entities, new molecular entities	54
2. Similar or equivalent “me-too” products	54
3. Second generation products	56
4. Generic drugs	57
E. Summary	58
III. SPECIFICITIES IN PHARMACEUTICALS AND RECENT DEVELOPMENTS	59
A. Innovating and inventing in pharmaceutical industry	59
1. Specificities in the drug development process	59
a) Highly regulated industry	59
b) R&D – a costly and lengthy road to a medicine	60
c) Uncertainties in post-invention development	64
(1) Scientific uncertainty: Unpredictability of substances	64
(2) Regulatory and market uncertainties	65
d) Information rich chemicals	66
2. Specificities in the market for pharmaceuticals	67
a) Imitation with negligible cost and much reduced risk	67
b) Prescription based purchase: A disconnection between choosers and payers	68
c) Information asymmetry and high loyalty to a medicine	69
d) Pricing	70
3. Specificities of the patent protection for pharmaceuticals	72
a) Patent protection for industrial technologies	72
b) Patent protection in the pharmaceutical industry	74
B. Challenges and overcoming efforts	76
1. Decreased R&D productivity	78
2. Dearth of new medical entities	80
a) Significance of NMEs	80
b) Decreased number of NMEs	80

c) Potential reasons for the decrease	83
(1) Decrease in solvable scientific problems	83
(2) Stringent safety regulations	84
(3) Problem of over-disclosure	84
(4) Early and numerous abandonments of potential candidates	85
3. Patent cliffs of blockbuster medications	86
4. Frequent merger and acquisitions (M&As) and in-licensing	86
5. Drastic increase of second generation inventions	88
a) Life cycle management or evergreening	89
b) Drastic increase of this activity supported by the number of second generation patents	91
C. Summary	93
IV. STANDARDS OF PATENTABILITY FOR PHARMACEUTICAL SELECTION INVENTIONS	95
A. Novelty and anticipation	96
1. Introduction	96
2. Examination of novelty	98
3. Inherent anticipation and enablement	103
4. Novelty of selection inventions	106
a) Species selection inventions	106
b) Optical isomers	117
c) Crystalline forms	127
d) Metabolite	130
5. Analysis and conclusion	133
B. Inventive step / Non-obviousness	134
1. Inventive step in patentability requirements	135
2. Examination of inventive step	136
3. Inventive step requirement for selection inventions	144
a) Species selection invention	144
b) Optical isomers	150
c) Crystalline forms	157
d) Metabolites	164
4. Analysis and conclusion	164
C. Disclosure requirement	167
1. Written description requirement	168

2.	Enablement requirement	171
a)	Enablement requirement	171
b)	Enablement requirements in the patent law	175
(1)	Enablement as a requirement for anticipation	175
(2)	Basic similarity of the two enablement requirements	176
(3)	Differences between the two enablement requirements	177
3.	Disclosure requirement of selection inventions	178
a)	Species selection invention	178
b)	Optical isomers	179
c)	Crystalline forms	180
D.	Conclusion	180
V.	IMPLICATIONS OF THE PATENTABILITY REQUIREMENTS ON INNOVATION AND COMPETITION IN THE PHARMACEUTICAL INDUSTRY	184
A.	Concerns about lowered patentability	185
1.	General concerns about lowered patentability	185
a)	Superfluous second generation patents	185
b)	Increased patent exclusivities and amplified uncertainties thereof	187
c)	Encouraged waste of resources	190
d)	Hindrance of pharmaceutical innovation	192
2.	Concerns about the novelty requirements	194
a)	Language dependent prior art disclosure problem	194
b)	Rendering inventive step requirement meaningless	196
c)	Potential concerns of “direct and unambiguous” disclosure requirement	198
B.	Implications considering the breadth of selection patents	198
1.	Scope of the protection	199
2.	Scope of selection patents	203
a)	Species selection patents	203
b)	Optical isomers	203
c)	Metabolite	206
d)	Polymorphs	208
3.	Analysis and conclusion	209

C.	Implications considering the length of selection patents	210
1.	Patent term and patent term extension	211
a)	In Europe	212
b)	In the United States	213
c)	In Korea	214
2.	Patent term extension on selection patents	215
a)	Species selection patents	215
b)	Optical isomers	215
c)	Polymorphs	218
d)	Metabolite	218
3.	Analysis and conclusion	218
D.	Implications on the competition in the pharmaceutical industry	222
1.	Introduction	222
2.	Quasi-obstacles of generics market entry	225
a)	Scope of second generation patents	225
b)	Length of second generation patents	227
c)	Delayed filing of second generation patent applications	227
3.	Real obstacles to generics' market entry	229
a)	Automatic thirty-month stay and new list up in the Orange Book in the United States	229
b)	Pendency of patent applications: Uncertainty	231
(1)	Pendency of patent applications	231
(2)	Filing of divisional applications	232
c)	Active movement of the market to new products	237
d)	Along with very specific patents on the secondary products	240
4.	Analysis and conclusion	242
E.	Summary and conclusion	243
VI.	PROPOSALS	245
A.	Introduction	247
B.	Nature of selection inventions	249
1.	Different natures of selection inventions	249
a)	Species selection invention	249
b)	Other selection inventions	251
2.	Selection inventions from the era of penicillin to the 21th century	251
a)	Early medications and the novelty requirement	251

b) “Made available to the public” for the first time	252
3. Analysis and conclusion	254
C. Proposals on the breadth of patents	255
1. Arguments on the breadth of patents	255
a) Arguments for a broader patent scope	256
b) Arguments against a broader patent scope	258
c) Arguments on patent scope with consideration of other relevant factors	260
2. Interim conclusion	261
3. Solutions to the overlapping scope with species selection invention	264
a) Voluntary licensing agreements	265
b) Non-voluntary licenses	266
(1) Compulsory licenses	267
(2) Case law relevant to compulsory licenses	269
c) Reverse doctrine of equivalents	272
d) Conclusion	274
D. Proposals on the length of patents	275
1. Arguments on the length of patents	275
2. Proposals on the length of patents	277
a) Proposal on the length of basic patents	277
(1) Introduction	277
(2) Proposed term of basic patents	278
(3) The basis of the proposal	279
(4) Expected effects	281
b) Proposal on the patent term extension of second generation patents	282
E. Proposals on the patentability requirements	283
1. Introduction: Technology specific patentability standards	283
2. Proposals on the novelty requirement	286
a) Arguments on the novelty requirement	286
b) Proposal on the novelty requirement of species selection invention	287
(1) Meaning of something “made available to the public” in the pharmaceutical industry	287
(2) A patent as a double-edged sword to NMEs	289

(3) Statutory exceptions to the novelty requirement and considerations thereof	290
(4) Proposed novelty requirement for NMEs	291
(5) Appreciation of the Olanzapine decision and its expected results	293
c) Discussion on the novelty requirement of other selection inventions	294
3. Proposals on the inventive step requirement	294
a) Arguments on the inventive step requirement	295
(1) Arguments for a strict inventive step requirement	295
(2) Arguments for a strict inventive step requirement together with broader protection	296
(3) Arguments against a strict inventive step requirement	297
(4) Arguments for the relaxed inventive step requirement in risky and expensive R&D fields	297
b) Proposal on the inventive step of species selection inventions	299
c) Proposal on the inventive step of other selection inventions	300
(1) Introduction	300
(2) Proposed standard to assess the inventive step	301
(3) Basis of the proposal	301
(4) Expected effects	304
4. Discussions on the sufficiency requirement	306
a) Discrepancy between the scope of and the disclosure of a genus claim	306
b) Stringent disclosure requirement of the basic invention	307
c) Conclusion	309
F. Conclusion	309
VII. FINAL CONCLUSIONS	312
List of Statutory Instruments	321
List of Case Laws	323
Bibliography	333

List of Abbreviations

AB	Appellate Body
ABPI	Association of the British Pharmaceutical Industry
Adv. Genet.	Advances in Genetics
aff'd	affirmed
AIPLA Q. J.	AIPLA Quarterly Journal
Aliment Pharm. Ther.	Alimentary Pharmacology & Therapeutics
Am. U. L. Rev.	American University Law Review
Art.	Article
B. C. L. Rev.	Boston College Law Review
BeckRS	Beck-Rechtsprechung
Bell J. Econ.	Bell Journal of Economics.
Berkeley Tech. L. J.	Berkeley Technology Law Journal
BGH	Bundesgerichtshof, Federal Supreme Court of Germany
Bioorgan. Med. Chem.	Bioorganic & Medicinal Chemistry
Biotechnol. Law Rep.	Biotechnology Law Report
BOA	Board of Appeal of the European Patent Office
BPatG	Bundespatentgericht, Federal Patent Court of Germany
BpatGE	Entscheidungen des Bundespatentgerichts
Brit. Med. J.	British Medical Journal
Brookings Paper on Econ. Activity	Brookings Paper on Economic Activity
B. U. L. Rev.	Boston University Law Review
Cal. L. R.	California Law Review
Case W. Res. L. Rev.	Case Western Reserve Law Review
cert.	certiorari
C.F.R.	Code of Federal Regulations
CIPA	Chartered Institute of Patent Attorneys
CJEU	Court of Justice of the European Union
Clin. Chem.	Clinical Chemistry
Clin. Dermatol.	Clinical Dermatology
Clin. Infect. Dis.	Clinical Infectious Diseases

List of Abbreviations

Clin. Microbiol. Infec.	Clinical Microbiology & Infection
Clin. Pharmacokinet.	Clinical Pharmacokinetics
Clin. Pharmacol. Ther.	Clinical Pharmacology & Therapeutics
Colum. L. Rev.	Columbia Law Review
Conn. J. Int'l L.	Connecticut Journal of International Law
Cornell L. Rev.	Cornell Law Review
Discov. Med.	Discovery Medicine
DPMA	Deutsches Patent- und Markenamt, German Patent and Trademark Office
Drug Discov. Today	Drug Discovery Today
Drug Info. J.	Drug Information Journal
Duke L. J.	Duke Law Journal
Econ. J.	The Economic Journal
e.g.	exempli gratia, for example
EFPIA	European Federation of Pharmaceutical Industries and Associations
EIPR	European Intellectual Property Review
Epilepsy Res.	Epilepsy Research
EPO	European Patent Office
Eur. J. Drug Metab. Ph.	European Journal of Drug Metabolism and Pharmacokinetics
Eur. J. Health L.	European Journal of Health Law
FDA	U.S. Food and Drug Administration
Fed. Law.	Federal Lawyer
Food & Drug L.J.	Food and Drug Law Journal
Fordham Int'l L. J.	Fordham International Law Journal
Fordham L. Rev.	Fordham Law Review
FTC	Federal Trade Commission
Geo. L. J.	Georgetown Law Journal
Geo. Mason L. Rev.	George Mason Law Review
GPA	German Patent Act
GRUR	Gewerblicher Rechtsschutz Und Urheberrecht
GRUR Int	Gewerblicher Rechtsschutz und Urheberrecht Internationaler Teil.
GRUR-Prax	Gewerblicher Rechtsschutz und Urheberrecht, Praxis im Immaterial- und Wettbewerbsrecht

GSK	GlaxoSmithKline
Harv. Int'l L. J.	Harvard International Law Journal
Harv. L. Rev.	Harvard Law Review
Health Affair.	Health Affairs
High Tech. L. J.	High Technology Law Journal
Hist. & Tech.	History and Technology
Hous L. Rev.	Houston Law Review
Hum. Psychopharm.	Human Psychopharmacology
ICTSD	International Centre for Trade and Sustainable Development
IDEA	IDEA: The Journal of Law and Technology
IDSAs	Infectious Diseases Society of America
IG Rule	The rule established in the I.G. Farbenindustrie's A.G.'s Patent case
IIC	International Review of Intellectual Property and Competition Law
Ill. L. Rev.	Illinois Law Review
IMD	Incrementally Modified Drugs
In Vivo: Bus. Med. Rep.	In vivo: The Business and Medicine Report
INN	International Non-proprietary Name
Int. J. Health Care Fi.	International Journal of Health Care Finance & Economics
Int. J. Ind. Organ.	International Journal of Industrial Organization
Intell. Prop. Q.	Intellectual Property Quarterly
IP	Intellectual Property
IPR	Intellectual Property Right
IR	Infrared
J. Chem. Inf. Comp. Sci.	Journal of Chemical Information and Computer Sciences
J. Copyright Soc'y U.S.A.	Journal of the Copyright Society of the USA
J. E. C. L. & Pract.	Journal of European Competition Law and Practice
J. Econ. Behav. Organ.	Journal of Economic Behavior & Organization
J. Econ. Manage. Strat.	Journal of Economics & Management Strategy
J. Econ. Perspect.	Journal of Economic Perspectives
J. Financ. Econ.	Journal of Financial Economics
J. Generic Med	Journal of Generic Medicine
J. Health Econ.	Journal of Health Economics

List of Abbreviations

J. Ind. Econ.	Journal of Industrial Economics
J. Law Econ.	Journal of Law & Economics
J. Legal Stud.	Journal of Legal Studies
J. Manage.	Journal of Management
J. Marketing Res.	Journal of Marketing Research
J. Med. Chem.	Journal of Medicinal Chemistry
J. Pat. & Trademark Off. Soc'y	Journal of the Patent and Trademark Office Society
J. Pat. Off. Soc'y	Journal of the Patent Office Society
J. Pharmaceut. Marketing Manage.	Journal of Pharmaceutical Marketing and Management
J. Tech. L. & Pol'y	Journal of Technology Law & Policy
J. Technol. Transfer	Journal of Technology Transfer
Lancet Infect. Dis.	Lancet Infectious Diseases
LJ	Lord Justice
Manage. Decis. Econ.	Managerial and Decision Economics
Manage. Sci.	Management Science
Mich. Telecomm. Tech. L. Rev.	Michigan Telecommunications and Technology Law Review
Minn. L. Rev.	Minnesota Law Review
Modern Drug Discov.	Modern Drug Discovery
Nat. Rev. Drug Discov.	Nature Reviews Drug Discovery
NBER	National Bureau of Economic Research
New Eng. J. Med.	New England Journal of Medicine
NIHCM	The National Institute for Health Care Management Research and Educational Foundation
NME	Mew Medical Entity or New Molecular Entity
NMR	Nuclear Magnetic Resonance
Nw. U. L. Rev.	Northwestern University Law Review
N.Y.U. L. Rev.	New York University Law Review
OECD	Organisation for Economic Co-operation and Development
Open Access J. Clin. Trials	Open Access Journal of Clinical Trials
OTC	Over-The-Counter
Para	paragraph
PCT	Patent Cooperation Treaty

PHC	Paroxetine hydrochloride
PHOSITA	The person having ordinary skill in the art
PLOS Med	Plos Medicine
Probl. Perspect. Manage.	Problems and Perspectives in Management
R&D	Research and Development
RAND J. Econ.	RAND Journal of Economics
<i>reh'g</i>	rehearing
Res. Policy	Research Policy
San. Diego L. Rev.	San Diego Law Review
Santa Clara Computer & High Tech. L. J.	Santa Clara Computer and High Technology Law Journal
SAR	Structure-Activity Relationship
Sci. & Pub. Pol'y	Science and Public Policy
Sec.	Section
Seton Hall L. Rev.	Seton Hall Law Review
SME	Small and Medium Enterprise
SMU L. Rev.	SMU Law Review
Soc. Philos. Policy	Social Philosophy & Policy
SPC	Supplementary Protection Certificate
St. John's J. Legal Comment.	St. John's Journal of Legal Commentary
Stan. Tech. L. Rev.	Stanford Technology Law Review
Sup. Ct. Rev.	Supreme Court Review
Tenn. L. Rev.	Tennessee Law Review
Tex. Intell. Prop. L.J.	Texas Intellectual Property Law Journal
Tex. L. Rev.	Texas Law Review
TFEU	Treaty on the Functioning of the European Union
THC	Terazosine hydrochloride
Trademark Rep.	Trademark Reporter
TRIPS	The Agreement on Trade Related Aspects of Intellectual Property Rights
Tul. J. Tech. & Intell. Prop.	Tulane Journal of Technology & Intellectual Property
U. Chi. L. Rev.	University of Chicago Law Review
UC Irvine L.R.	UC Irvine Law Review
U. Dayton L. Rev.	University of Dayton Law Review
U.K.	United Kingdom
UNCTAD	United Nations Conference on Trade and Development

List of Abbreviations

U. Pa. J. Int'l Econ. L.	University of Pennsylvania Journal of International Economic Law
U.S.	United States
U.S.C.	United States Code
USPTO	U.S. Patent & Trademark Office
Va. L. Rev.	Virginia Law Review
Vand. L. Rev.	Vanderbilt Law Review
Wake Forest L. Rev.	Wake Forest Law Review
Wash. U. J. L. & Pol'y	Washington University Journal of Law and Policy
Wash. U. L. Rev.	Washington University Law Review
WHO	World Health Organization
Wid. L. Symp. J.	Widner Law Symposium Journal
WIPO	World Intellectual Property Organization
Wm. & Mary L. Rev.	William and Mary Law Review
World Pat. Info.	World Patent Information
WTO	World Trade Organization
XRPD	X-ray powder diffraction
Yale J. Health Pol'y L. & Ethics	Yale Journal of Health Policy, Law, and Ethics
Yale L. J.	Yale Law Journal